Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;168(1):99-109.
doi: 10.1007/s11060-024-04651-0. Epub 2024 Apr 17.

Improved outcomes for triple negative breast cancer brain metastases patients after stereotactic radiosurgery and new systemic approaches

Elad Mashiach  1 , Juan Diego Alzate  2 , Fernando De Nigris Vasconcellos  2 , Sylvia Adams  3   4 , Brandon Santhumayor  2 , Ying Meng  2 , Zane Schnurman  2 , Bernadine R Donahue  5   6 , Kenneth Bernstein  5 , Cordelia Orillac  2 , Rishitha Bollam  3   4 , Maryann J Kwa  3   4 , Marleen Meyers  3   4 , Ruth Oratz  3   4 , Yelena Novik  3   4 , Joshua S Silverman  5 , David H Harter  2 , John G Golfinos  2 , Douglas Kondziolka  2
Affiliations

Improved outcomes for triple negative breast cancer brain metastases patients after stereotactic radiosurgery and new systemic approaches

Elad Mashiach et al. J Neurooncol. 2024 May.

Abstract

Purpose: Although ongoing studies are assessing the efficacy of new systemic therapies for patients with triple negative breast cancer (TNBC), the overwhelming majority have excluded patients with brain metastases (BM). Therefore, we aim to characterize systemic therapies and outcomes in a cohort of patients with TNBC and BM managed with stereotactic radiosurgery (SRS) and delineate predictors of increased survival.

Methods: We used our prospective patient registry to evaluate data from 2012 to 2023. We included patients who received SRS for TNBC-BM. A competing risk analysis was conducted to assess local and distant control.

Results: Forty-three patients with 262 tumors were included. The median overall survival (OS) was 16 months (95% CI 13-19 months). Predictors of increased OS after initial SRS include Breast GPA score > 1 (p < 0.001) and use of immunotherapy such as pembrolizumab (p = 0.011). The median time on immunotherapy was 8 months (IQR 4.4, 11.2). The median time to new CNS lesions after the first SRS treatment was 17 months (95% CI 12-22). The cumulative rate for development of new CNS metastases after initial SRS at 6 months, 1 year, and 2 years was 23%, 40%, and 70%, respectively. Thirty patients (70%) underwent multiple SRS treatments, with a median time of 5 months (95% CI 0.59-9.4 months) for the appearance of new CNS metastases after second SRS treatment.

Conclusions: TNBC patients with BM can achieve longer survival than might have been previously anticipated with median survival now surpassing one year. The use of immunotherapy is associated with increased median OS of 23 months.

Keywords: Brain metastases; Breast cancer; Gamma knife; Immunotherapy; Neuro oncology; Stereotactic radiosurgery; Triple negative breast cancer.

PubMed Disclaimer

References

    1. Mashiach E, Alzate JD, De Nigris Vasconcellos F, Bernstein K, Donahue BR, Schnurman Z, Gurewitz J, Rotman LE, Adams S, Meyers M, Oratz R, Novik Y, Kwa MJ, Silverman JS, Sulman EP, Golfinos JG, Kondziolka D (2023) Long-term Survival From Breast Cancer Brain Metastases in the Era of Modern Systemic Therapies. Neurosurgery https://doi.org/10.1227/neu.0000000000002640
    1. Kim JS, Kim IA (2020) Evolving treatment strategies of brain metastases from breast cancer: current status and future direction. Ther Adv Med Oncol 12:1758835920936117. https://doi.org/10.1177/1758835920936117 - DOI - PubMed - PMC
    1. Niikura N, Hayashi N, Masuda N, Takashima S, Nakamura R, Watanabe K, Kanbayashi C, Ishida M, Hozumi Y, Tsuneizumi M, Kondo N, Naito Y, Honda Y, Matsui A, Fujisawa T, Oshitanai R, Yasojima H, Tokuda Y, Saji S, Iwata H (2014) Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. Breast Cancer Res Treat 147:103–112. https://doi.org/10.1007/s10549-014-3090-8 - DOI - PubMed
    1. Morris PG, Murphy CG, Mallam D, Accordino M, Patil S, Howard J, Omuro A, Beal K, Seidman AD, Hudis CA, Fornier MN (2012) Limited overall survival in patients with brain metastases from triple negative breast cancer. Breast J 18:345–350. https://doi.org/10.1111/j.1524-4741.2012.01246.x - DOI - PubMed
    1. Kim YJ, Kim JS, Kim IA (2018) Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database. J Cancer Res Clin Oncol 144:1803–1816. https://doi.org/10.1007/s00432-018-2697-2 - DOI - PubMed

LinkOut - more resources